| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Muscle, Skeletal | 49 | 2023 | 396 | 8.700 |
Why?
|
| Cachexia | 34 | 2023 | 54 | 8.080 |
Why?
|
| NF-kappa B | 48 | 2019 | 432 | 7.630 |
Why?
|
| Muscle Development | 16 | 2017 | 31 | 4.440 |
Why?
|
| Signal Transduction | 44 | 2022 | 2689 | 3.280 |
Why?
|
| Neoplasms | 16 | 2023 | 1667 | 2.380 |
Why?
|
| Transcription Factor RelA | 17 | 2013 | 47 | 2.230 |
Why?
|
| Pancreatic Neoplasms | 9 | 2022 | 332 | 2.080 |
Why?
|
| I-kappa B Kinase | 19 | 2018 | 40 | 1.950 |
Why?
|
| Rhabdomyosarcoma | 7 | 2017 | 36 | 1.760 |
Why?
|
| Muscular Dystrophy, Duchenne | 7 | 2018 | 20 | 1.670 |
Why?
|
| Myoblasts | 10 | 2021 | 22 | 1.660 |
Why?
|
| Mice | 74 | 2022 | 8474 | 1.640 |
Why?
|
| Animals | 97 | 2022 | 20881 | 1.620 |
Why?
|
| Gene Expression Regulation, Developmental | 7 | 2017 | 328 | 1.620 |
Why?
|
| MicroRNAs | 10 | 2021 | 447 | 1.390 |
Why?
|
| Muscular Atrophy | 9 | 2016 | 35 | 1.330 |
Why?
|
| Cell Differentiation | 12 | 2017 | 1034 | 1.280 |
Why?
|
| Muscular Diseases | 6 | 2015 | 41 | 1.270 |
Why?
|
| Muscle Proteins | 9 | 2015 | 94 | 1.270 |
Why?
|
| Tumor Necrosis Factor-alpha | 18 | 2017 | 626 | 1.260 |
Why?
|
| Gene Expression Regulation, Neoplastic | 10 | 2017 | 756 | 1.240 |
Why?
|
| Myoblasts, Skeletal | 4 | 2013 | 5 | 1.100 |
Why?
|
| MyoD Protein | 3 | 2016 | 13 | 0.990 |
Why?
|
| Transforming Growth Factor beta | 5 | 2015 | 384 | 0.940 |
Why?
|
| Cell Respiration | 2 | 2016 | 47 | 0.930 |
Why?
|
| Cytokines | 11 | 2017 | 866 | 0.920 |
Why?
|
| Macrophages | 7 | 2018 | 647 | 0.880 |
Why?
|
| Adenocarcinoma | 6 | 2017 | 475 | 0.840 |
Why?
|
| I-kappa B Proteins | 10 | 2009 | 47 | 0.780 |
Why?
|
| Bone Neoplasms | 3 | 2017 | 100 | 0.760 |
Why?
|
| Disease Models, Animal | 17 | 2019 | 2550 | 0.750 |
Why?
|
| Mitochondria | 6 | 2016 | 643 | 0.740 |
Why?
|
| Chemokine CCL2 | 2 | 2018 | 101 | 0.730 |
Why?
|
| Neoplasms, Experimental | 3 | 2017 | 118 | 0.710 |
Why?
|
| Dystrophin | 4 | 2011 | 6 | 0.700 |
Why?
|
| Humans | 84 | 2023 | 68618 | 0.690 |
Why?
|
| Inflammation | 8 | 2018 | 1030 | 0.670 |
Why?
|
| Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 2 | 2016 | 51 | 0.660 |
Why?
|
| Proteasome Endopeptidase Complex | 6 | 2009 | 69 | 0.650 |
Why?
|
| Cell Transformation, Neoplastic | 6 | 2016 | 235 | 0.650 |
Why?
|
| Carcinoma, Pancreatic Ductal | 4 | 2022 | 46 | 0.650 |
Why?
|
| YY1 Transcription Factor | 2 | 2008 | 6 | 0.620 |
Why?
|
| Fibroblasts | 9 | 2022 | 902 | 0.610 |
Why?
|
| Cells, Cultured | 15 | 2018 | 2673 | 0.610 |
Why?
|
| Down-Regulation | 7 | 2018 | 447 | 0.610 |
Why?
|
| Mice, Transgenic | 12 | 2018 | 1033 | 0.610 |
Why?
|
| Immunologic Surveillance | 1 | 2017 | 10 | 0.600 |
Why?
|
| Growth Differentiation Factor 15 | 1 | 2017 | 18 | 0.590 |
Why?
|
| Electrophoretic Mobility Shift Assay | 5 | 2012 | 60 | 0.570 |
Why?
|
| Neoplasm Proteins | 4 | 2017 | 307 | 0.560 |
Why?
|
| Gene Expression Regulation | 14 | 2018 | 1293 | 0.560 |
Why?
|
| Mice, Inbred mdx | 9 | 2018 | 10 | 0.540 |
Why?
|
| DNA-Binding Proteins | 8 | 2013 | 700 | 0.540 |
Why?
|
| Ephrin-A5 | 1 | 2016 | 1 | 0.540 |
Why?
|
| Regeneration | 3 | 2015 | 105 | 0.530 |
Why?
|
| Antigens | 1 | 2016 | 90 | 0.530 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2013 | 216 | 0.520 |
Why?
|
| Proteoglycans | 1 | 2016 | 103 | 0.510 |
Why?
|
| Mice, Knockout | 13 | 2019 | 1692 | 0.510 |
Why?
|
| Peptide Fragments | 1 | 2018 | 483 | 0.510 |
Why?
|
| Apoptosis | 13 | 2019 | 1641 | 0.500 |
Why?
|
| Cell Line, Tumor | 18 | 2022 | 1851 | 0.500 |
Why?
|
| Cyclin D1 | 2 | 2009 | 37 | 0.500 |
Why?
|
| Muscle Fibers, Skeletal | 3 | 2015 | 20 | 0.500 |
Why?
|
| Myocytes, Cardiac | 1 | 2018 | 442 | 0.490 |
Why?
|
| Cell Line | 18 | 2021 | 1752 | 0.490 |
Why?
|
| PAX7 Transcription Factor | 2 | 2013 | 2 | 0.480 |
Why?
|
| Nuclear Proteins | 2 | 2013 | 271 | 0.470 |
Why?
|
| Head and Neck Neoplasms | 8 | 2015 | 561 | 0.460 |
Why?
|
| ELAV Proteins | 1 | 2013 | 17 | 0.450 |
Why?
|
| Lipolysis | 1 | 2012 | 13 | 0.420 |
Why?
|
| Cellular Senescence | 2 | 2012 | 112 | 0.420 |
Why?
|
| Muscular Dystrophies | 2 | 2012 | 17 | 0.410 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 65 | 0.410 |
Why?
|
| GTP-Binding Protein alpha Subunits, G12-G13 | 1 | 2011 | 1 | 0.400 |
Why?
|
| Cell Cycle | 3 | 2009 | 312 | 0.400 |
Why?
|
| Heterografts | 4 | 2019 | 70 | 0.390 |
Why?
|
| Colonic Neoplasms | 4 | 2015 | 299 | 0.390 |
Why?
|
| Mice, Inbred C57BL | 12 | 2019 | 2791 | 0.390 |
Why?
|
| Transcription, Genetic | 10 | 2018 | 562 | 0.390 |
Why?
|
| Homeostasis | 1 | 2012 | 291 | 0.380 |
Why?
|
| Protein Biosynthesis | 1 | 2011 | 181 | 0.380 |
Why?
|
| Neoplasm Transplantation | 5 | 2019 | 160 | 0.370 |
Why?
|
| STAT3 Transcription Factor | 3 | 2017 | 86 | 0.370 |
Why?
|
| Receptor, Notch1 | 1 | 2010 | 11 | 0.370 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2010 | 33 | 0.360 |
Why?
|
| Muscles | 2 | 2016 | 158 | 0.360 |
Why?
|
| MAP Kinase Kinase Kinases | 3 | 2017 | 34 | 0.360 |
Why?
|
| Transcription Factors | 7 | 2016 | 753 | 0.360 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2011 | 167 | 0.350 |
Why?
|
| Antineoplastic Agents | 5 | 2018 | 1070 | 0.350 |
Why?
|
| DNA Methylation | 2 | 2010 | 193 | 0.340 |
Why?
|
| Immunity, Innate | 3 | 2018 | 156 | 0.340 |
Why?
|
| Genomic Instability | 1 | 2009 | 41 | 0.330 |
Why?
|
| Promoter Regions, Genetic | 4 | 2010 | 615 | 0.330 |
Why?
|
| Male | 27 | 2019 | 37321 | 0.330 |
Why?
|
| RNA, Messenger | 8 | 2014 | 1664 | 0.320 |
Why?
|
| DNA Repair | 1 | 2009 | 127 | 0.320 |
Why?
|
| Gene Regulatory Networks | 1 | 2009 | 94 | 0.320 |
Why?
|
| Sarcopenia | 2 | 2021 | 9 | 0.310 |
Why?
|
| Interleukin-6 | 5 | 2018 | 330 | 0.300 |
Why?
|
| Sarcoma, Ewing | 2 | 2017 | 26 | 0.300 |
Why?
|
| Peptides | 6 | 2017 | 455 | 0.290 |
Why?
|
| Myofibrils | 1 | 2007 | 35 | 0.290 |
Why?
|
| Female | 30 | 2019 | 38074 | 0.280 |
Why?
|
| Osteosarcoma | 2 | 2017 | 35 | 0.280 |
Why?
|
| Toll-Like Receptor 7 | 2 | 2018 | 17 | 0.280 |
Why?
|
| Myostatin | 3 | 2012 | 9 | 0.270 |
Why?
|
| Cell Survival | 9 | 2017 | 901 | 0.270 |
Why?
|
| Interferon-gamma | 6 | 2013 | 241 | 0.270 |
Why?
|
| Chromatin Immunoprecipitation | 4 | 2012 | 52 | 0.270 |
Why?
|
| Transcriptional Activation | 7 | 2012 | 226 | 0.270 |
Why?
|
| Gene Silencing | 5 | 2018 | 137 | 0.270 |
Why?
|
| Myosin Heavy Chains | 2 | 2013 | 49 | 0.270 |
Why?
|
| Dystrophin-Associated Proteins | 1 | 2005 | 7 | 0.270 |
Why?
|
| Disease Progression | 6 | 2019 | 1038 | 0.260 |
Why?
|
| Mice, SCID | 6 | 2017 | 238 | 0.260 |
Why?
|
| Blotting, Western | 7 | 2012 | 954 | 0.260 |
Why?
|
| Sarcoma | 2 | 2016 | 70 | 0.260 |
Why?
|
| DNA Damage | 2 | 2019 | 190 | 0.250 |
Why?
|
| Thrombin | 2 | 1997 | 117 | 0.250 |
Why?
|
| Biomarkers, Tumor | 4 | 2018 | 508 | 0.250 |
Why?
|
| Models, Genetic | 2 | 2017 | 161 | 0.250 |
Why?
|
| Muscle Contraction | 3 | 2016 | 210 | 0.240 |
Why?
|
| Phosphorylation | 11 | 2018 | 1200 | 0.240 |
Why?
|
| Oxidation-Reduction | 3 | 2016 | 567 | 0.240 |
Why?
|
| Ubiquitin-Protein Ligases | 5 | 2015 | 89 | 0.240 |
Why?
|
| Extracellular Vesicles | 2 | 2021 | 21 | 0.240 |
Why?
|
| Glycoproteins | 1 | 2005 | 238 | 0.230 |
Why?
|
| Interferon-alpha | 2 | 2018 | 46 | 0.230 |
Why?
|
| Adipose Tissue | 3 | 2022 | 221 | 0.230 |
Why?
|
| Repressor Proteins | 4 | 2018 | 183 | 0.230 |
Why?
|
| Mice, Nude | 4 | 2013 | 294 | 0.230 |
Why?
|
| Anorexia | 2 | 2022 | 7 | 0.220 |
Why?
|
| Cytoskeletal Proteins | 3 | 2014 | 108 | 0.220 |
Why?
|
| Protein Binding | 6 | 2016 | 1027 | 0.220 |
Why?
|
| Gene Expression Profiling | 4 | 2016 | 498 | 0.220 |
Why?
|
| Trans-Activators | 5 | 2013 | 237 | 0.220 |
Why?
|
| Animals, Newborn | 3 | 2016 | 396 | 0.220 |
Why?
|
| Muscle Neoplasms | 2 | 2014 | 9 | 0.220 |
Why?
|
| Calcium | 2 | 2018 | 929 | 0.220 |
Why?
|
| Antigens, Neoplasm | 2 | 2014 | 132 | 0.210 |
Why?
|
| Apigenin | 2 | 2016 | 10 | 0.210 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 468 | 0.210 |
Why?
|
| Cell Proliferation | 7 | 2017 | 1174 | 0.210 |
Why?
|
| Stress, Physiological | 2 | 2019 | 215 | 0.200 |
Why?
|
| Osteoblasts | 3 | 2019 | 99 | 0.200 |
Why?
|
| Prognosis | 3 | 2023 | 2093 | 0.200 |
Why?
|
| Interleukin-8 | 3 | 2017 | 71 | 0.200 |
Why?
|
| NF-KappaB Inhibitor alpha | 7 | 2018 | 28 | 0.200 |
Why?
|
| Genes, Reporter | 3 | 2013 | 191 | 0.190 |
Why?
|
| Wasting Syndrome | 2 | 2014 | 3 | 0.190 |
Why?
|
| Protein Processing, Post-Translational | 4 | 2018 | 284 | 0.190 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2009 | 411 | 0.190 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2008 | 629 | 0.190 |
Why?
|
| Aged | 11 | 2018 | 14862 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2017 | 174 | 0.190 |
Why?
|
| Luciferases | 3 | 2012 | 105 | 0.180 |
Why?
|
| Aminopyridines | 2 | 2017 | 26 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 3 | 2016 | 331 | 0.180 |
Why?
|
| Gene Deletion | 3 | 2017 | 235 | 0.180 |
Why?
|
| Monocytes | 3 | 2011 | 210 | 0.180 |
Why?
|
| Sepsis | 2 | 2016 | 233 | 0.180 |
Why?
|
| Histone Deacetylase 1 | 2 | 2018 | 32 | 0.180 |
Why?
|
| Models, Biological | 4 | 2016 | 981 | 0.170 |
Why?
|
| Alpha-Ketoglutarate-Dependent Dioxygenase FTO | 1 | 2019 | 4 | 0.170 |
Why?
|
| Transcriptome | 2 | 2019 | 164 | 0.170 |
Why?
|
| Computational Biology | 2 | 2013 | 190 | 0.170 |
Why?
|
| Gene Ontology | 1 | 2019 | 31 | 0.170 |
Why?
|
| Boronic Acids | 2 | 2009 | 40 | 0.160 |
Why?
|
| Pyrazines | 2 | 2009 | 46 | 0.160 |
Why?
|
| Toll-Like Receptor 8 | 1 | 2018 | 3 | 0.160 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2018 | 12 | 0.160 |
Why?
|
| Sin3 Histone Deacetylase and Corepressor Complex | 1 | 2018 | 3 | 0.160 |
Why?
|
| CCCTC-Binding Factor | 1 | 2018 | 5 | 0.160 |
Why?
|
| Serine | 2 | 2011 | 99 | 0.160 |
Why?
|
| Zinc | 2 | 2010 | 73 | 0.160 |
Why?
|
| Bone and Bones | 1 | 2019 | 145 | 0.160 |
Why?
|
| Binding Sites | 3 | 2016 | 631 | 0.160 |
Why?
|
| Hematopoiesis | 2 | 2016 | 108 | 0.160 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2018 | 23 | 0.160 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2016 | 29 | 0.160 |
Why?
|
| SAM Domain and HD Domain-Containing Protein 1 | 1 | 2018 | 1 | 0.160 |
Why?
|
| Receptors, Cell Surface | 4 | 2011 | 248 | 0.160 |
Why?
|
| Cell Division | 1 | 1999 | 541 | 0.160 |
Why?
|
| Transfection | 4 | 2007 | 782 | 0.160 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2016 | 331 | 0.160 |
Why?
|
| Forkhead Transcription Factors | 3 | 2015 | 94 | 0.160 |
Why?
|
| Sodium-Calcium Exchanger | 1 | 2018 | 69 | 0.150 |
Why?
|
| Cell Death | 3 | 2018 | 329 | 0.150 |
Why?
|
| Sulfonamides | 2 | 2017 | 141 | 0.150 |
Why?
|
| Phosphoproteins | 2 | 2014 | 202 | 0.150 |
Why?
|
| Virus Diseases | 1 | 2018 | 31 | 0.150 |
Why?
|
| Neovascularization, Pathologic | 2 | 2016 | 183 | 0.150 |
Why?
|
| Weight Loss | 3 | 2015 | 319 | 0.150 |
Why?
|
| Erlotinib Hydrochloride | 1 | 2017 | 12 | 0.150 |
Why?
|
| Myogenin | 1 | 1997 | 9 | 0.150 |
Why?
|
| Liposarcoma, Myxoid | 2 | 2016 | 5 | 0.150 |
Why?
|
| Rhabdomyosarcoma, Alveolar | 1 | 2017 | 2 | 0.150 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2012 | 118 | 0.150 |
Why?
|
| Middle Aged | 10 | 2018 | 21147 | 0.150 |
Why?
|
| Antibodies, Neutralizing | 1 | 2017 | 46 | 0.150 |
Why?
|
| Circadian Rhythm | 1 | 2018 | 218 | 0.150 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 213 | 0.150 |
Why?
|
| Cyclins | 1 | 1997 | 50 | 0.150 |
Why?
|
| Nitric Oxide | 2 | 2017 | 382 | 0.150 |
Why?
|
| Cell Nucleus | 4 | 2012 | 305 | 0.150 |
Why?
|
| Laboratory Personnel | 1 | 2016 | 1 | 0.140 |
Why?
|
| Aging | 2 | 2014 | 911 | 0.140 |
Why?
|
| Cell-Penetrating Peptides | 1 | 2016 | 8 | 0.140 |
Why?
|
| Transcription Factor RelB | 1 | 2016 | 4 | 0.140 |
Why?
|
| Protein Interaction Maps | 1 | 2016 | 30 | 0.140 |
Why?
|
| Peptides, Cyclic | 1 | 2016 | 35 | 0.140 |
Why?
|
| Sarcoma, Experimental | 1 | 2016 | 5 | 0.140 |
Why?
|
| Pancreatectomy | 1 | 2017 | 129 | 0.140 |
Why?
|
| Carrier Proteins | 3 | 2014 | 597 | 0.140 |
Why?
|
| Interleukin-1 | 3 | 2006 | 86 | 0.140 |
Why?
|
| Liposarcoma | 2 | 2016 | 13 | 0.140 |
Why?
|
| Nutritional Status | 1 | 2017 | 112 | 0.140 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2016 | 223 | 0.140 |
Why?
|
| Sp1 Transcription Factor | 1 | 1996 | 21 | 0.140 |
Why?
|
| 3T3 Cells | 3 | 2009 | 124 | 0.140 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2016 | 20 | 0.140 |
Why?
|
| Immunohistochemistry | 6 | 2014 | 1174 | 0.140 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2016 | 82 | 0.140 |
Why?
|
| Quantitative Trait Loci | 1 | 2016 | 35 | 0.140 |
Why?
|
| Leukemic Infiltration | 1 | 2016 | 2 | 0.140 |
Why?
|
| Mutation | 2 | 2013 | 1213 | 0.140 |
Why?
|
| Cell Movement | 2 | 2016 | 630 | 0.140 |
Why?
|
| Azepines | 1 | 2016 | 15 | 0.130 |
Why?
|
| Research Personnel | 1 | 2016 | 83 | 0.130 |
Why?
|
| Mitochondria, Muscle | 1 | 2016 | 12 | 0.130 |
Why?
|
| Mice, Inbred Strains | 3 | 2014 | 181 | 0.130 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2017 | 304 | 0.130 |
Why?
|
| Triazoles | 1 | 2016 | 43 | 0.130 |
Why?
|
| Troponin | 1 | 2015 | 25 | 0.130 |
Why?
|
| Phenylbutyrates | 1 | 2015 | 7 | 0.130 |
Why?
|
| Smad3 Protein | 1 | 2015 | 33 | 0.130 |
Why?
|
| Energy Metabolism | 2 | 2016 | 222 | 0.130 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 2015 | 40 | 0.130 |
Why?
|
| Immunoprecipitation | 2 | 2013 | 132 | 0.130 |
Why?
|
| Mice, Inbred BALB C | 4 | 2016 | 532 | 0.130 |
Why?
|
| Muscle Weakness | 1 | 2015 | 26 | 0.130 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2016 | 64 | 0.130 |
Why?
|
| Lisinopril | 1 | 2015 | 16 | 0.130 |
Why?
|
| Receptors, Melanocortin | 1 | 2015 | 5 | 0.130 |
Why?
|
| Bone Resorption | 1 | 2015 | 64 | 0.130 |
Why?
|
| Spironolactone | 1 | 2015 | 13 | 0.130 |
Why?
|
| Aldosterone | 1 | 2015 | 51 | 0.130 |
Why?
|
| Autophagy | 2 | 2018 | 208 | 0.130 |
Why?
|
| NADPH Oxidases | 1 | 2015 | 80 | 0.130 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2016 | 116 | 0.130 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 84 | 0.130 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 194 | 0.130 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2015 | 56 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type II | 3 | 2011 | 201 | 0.120 |
Why?
|
| Extracellular Matrix | 3 | 2012 | 493 | 0.120 |
Why?
|
| DNA | 3 | 2009 | 597 | 0.120 |
Why?
|
| Gene Knock-In Techniques | 2 | 2012 | 35 | 0.120 |
Why?
|
| Antibodies, Monoclonal | 1 | 2017 | 511 | 0.120 |
Why?
|
| Oxygen Consumption | 1 | 2016 | 258 | 0.120 |
Why?
|
| Hydrogen Peroxide | 2 | 2019 | 168 | 0.120 |
Why?
|
| Glioma | 1 | 2016 | 140 | 0.120 |
Why?
|
| Histone Deacetylase Inhibitors | 1 | 2015 | 116 | 0.120 |
Why?
|
| Critical Illness | 1 | 2016 | 191 | 0.120 |
Why?
|
| Adaptive Immunity | 1 | 2014 | 37 | 0.120 |
Why?
|
| Diaphragm | 2 | 2011 | 22 | 0.120 |
Why?
|
| Organelles | 1 | 2014 | 18 | 0.120 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2011 | 282 | 0.120 |
Why?
|
| Precancerous Conditions | 1 | 2014 | 74 | 0.120 |
Why?
|
| Myeloid Cells | 2 | 2012 | 57 | 0.120 |
Why?
|
| Metabolomics | 1 | 2014 | 28 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 102 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2016 | 234 | 0.120 |
Why?
|
| Satellite Cells, Skeletal Muscle | 1 | 2013 | 12 | 0.120 |
Why?
|
| Blood Proteins | 1 | 2014 | 94 | 0.110 |
Why?
|
| Tumor Necrosis Factor alpha-Induced Protein 3 | 1 | 2013 | 7 | 0.110 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2013 | 7 | 0.110 |
Why?
|
| ras Proteins | 1 | 2014 | 102 | 0.110 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2016 | 231 | 0.110 |
Why?
|
| Protein Isoforms | 3 | 2016 | 246 | 0.110 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2013 | 127 | 0.110 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 56 | 0.110 |
Why?
|
| TNF Receptor-Associated Factor 6 | 1 | 2013 | 14 | 0.110 |
Why?
|
| Motor Neurons | 1 | 2014 | 98 | 0.110 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2013 | 40 | 0.110 |
Why?
|
| Lipopolysaccharides | 3 | 2016 | 455 | 0.110 |
Why?
|
| Immunoglobulin G | 3 | 2016 | 481 | 0.110 |
Why?
|
| Microglia | 1 | 2014 | 143 | 0.110 |
Why?
|
| Dexamethasone | 1 | 1993 | 150 | 0.110 |
Why?
|
| Sequence Analysis, DNA | 1 | 2013 | 208 | 0.110 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2014 | 99 | 0.110 |
Why?
|
| Activins | 1 | 2012 | 4 | 0.110 |
Why?
|
| Testis | 1 | 2012 | 37 | 0.110 |
Why?
|
| Testicular Neoplasms | 1 | 2012 | 27 | 0.100 |
Why?
|
| Rats | 7 | 2008 | 5300 | 0.100 |
Why?
|
| CHO Cells | 2 | 2004 | 161 | 0.100 |
Why?
|
| Cricetinae | 2 | 2004 | 262 | 0.100 |
Why?
|
| Lymphopoiesis | 1 | 2012 | 16 | 0.100 |
Why?
|
| Aged, 80 and over | 5 | 2013 | 4848 | 0.100 |
Why?
|
| Case-Control Studies | 2 | 2013 | 1553 | 0.100 |
Why?
|
| Oligonucleotide Probes | 1 | 2012 | 35 | 0.100 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2012 | 110 | 0.100 |
Why?
|
| Embryo, Mammalian | 2 | 2005 | 176 | 0.100 |
Why?
|
| Phosphorus Radioisotopes | 1 | 2012 | 29 | 0.100 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 371 | 0.100 |
Why?
|
| Isotope Labeling | 1 | 2012 | 30 | 0.100 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 2011 | 26 | 0.100 |
Why?
|
| Dogs | 3 | 2017 | 490 | 0.100 |
Why?
|
| Esophageal Neoplasms | 2 | 2010 | 150 | 0.100 |
Why?
|
| Immunoenzyme Techniques | 1 | 2012 | 196 | 0.100 |
Why?
|
| Acute-Phase Reaction | 1 | 2011 | 10 | 0.100 |
Why?
|
| Utrophin | 1 | 2011 | 1 | 0.100 |
Why?
|
| Muscular Dystrophy, Animal | 1 | 2011 | 4 | 0.100 |
Why?
|
| Cell Dedifferentiation | 1 | 2011 | 4 | 0.100 |
Why?
|
| Receptors, Interleukin-4 | 1 | 2011 | 9 | 0.100 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 215 | 0.100 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2013 | 32 | 0.100 |
Why?
|
| Interferons | 1 | 2011 | 36 | 0.100 |
Why?
|
| Tumor Escape | 1 | 2011 | 37 | 0.100 |
Why?
|
| Stilbenes | 1 | 2011 | 57 | 0.090 |
Why?
|
| Lung Neoplasms | 2 | 2017 | 1173 | 0.090 |
Why?
|
| Zebrafish Proteins | 2 | 2002 | 100 | 0.090 |
Why?
|
| Enhancer of Zeste Homolog 2 Protein | 1 | 2010 | 13 | 0.090 |
Why?
|
| Polycomb Repressive Complex 2 | 1 | 2010 | 13 | 0.090 |
Why?
|
| Protein Kinase C | 1 | 2011 | 270 | 0.090 |
Why?
|
| Dependovirus | 1 | 2010 | 34 | 0.090 |
Why?
|
| Young Adult | 4 | 2016 | 5717 | 0.090 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2016 | 710 | 0.090 |
Why?
|
| B-Lymphocytes | 1 | 2012 | 329 | 0.090 |
Why?
|
| Stem Cells | 1 | 2011 | 248 | 0.090 |
Why?
|
| Adult | 8 | 2016 | 21403 | 0.090 |
Why?
|
| Homeodomain Proteins | 1 | 2010 | 157 | 0.090 |
Why?
|
| Membrane Proteins | 2 | 2012 | 617 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2010 | 64 | 0.090 |
Why?
|
| Myocardial Contraction | 1 | 2011 | 383 | 0.090 |
Why?
|
| Lung | 2 | 2016 | 849 | 0.090 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2010 | 139 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 2011 | 189 | 0.090 |
Why?
|
| Proteinuria | 1 | 2010 | 136 | 0.090 |
Why?
|
| Cyclooxygenase 2 | 2 | 2008 | 160 | 0.090 |
Why?
|
| Cerebellar Neoplasms | 1 | 2009 | 17 | 0.090 |
Why?
|
| Plasmids | 2 | 2007 | 258 | 0.080 |
Why?
|
| Medulloblastoma | 1 | 2009 | 24 | 0.080 |
Why?
|
| Translocation, Genetic | 1 | 2009 | 74 | 0.080 |
Why?
|
| Gene Transfer Techniques | 3 | 2010 | 173 | 0.080 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2009 | 44 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 2 | 2011 | 322 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2016 | 90 | 0.080 |
Why?
|
| Feedback, Physiological | 1 | 2008 | 38 | 0.080 |
Why?
|
| Protein Stability | 1 | 2009 | 90 | 0.080 |
Why?
|
| Protein Subunits | 1 | 2009 | 99 | 0.080 |
Why?
|
| Nucleic Acid Conformation | 1 | 2008 | 92 | 0.080 |
Why?
|
| Genetic Therapy | 1 | 2010 | 291 | 0.080 |
Why?
|
| Spleen | 3 | 2016 | 301 | 0.080 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2018 | 1745 | 0.080 |
Why?
|
| Myocardium | 2 | 2011 | 1204 | 0.080 |
Why?
|
| Immunocompetence | 1 | 2008 | 19 | 0.080 |
Why?
|
| Quality of Life | 3 | 2018 | 1515 | 0.080 |
Why?
|
| Tripartite Motif Proteins | 3 | 2015 | 7 | 0.080 |
Why?
|
| Proteomics | 1 | 2010 | 246 | 0.080 |
Why?
|
| Curcumin | 1 | 2008 | 23 | 0.080 |
Why?
|
| Pyrophosphatases | 1 | 2007 | 6 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2009 | 163 | 0.080 |
Why?
|
| HeLa Cells | 2 | 2016 | 237 | 0.070 |
Why?
|
| Chondrocytes | 1 | 2007 | 27 | 0.070 |
Why?
|
| Herpesvirus 4, Human | 1 | 2007 | 30 | 0.070 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 306 | 0.070 |
Why?
|
| Parathyroid Hormone-Related Protein | 1 | 2007 | 15 | 0.070 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2007 | 11 | 0.070 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2007 | 24 | 0.070 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2007 | 114 | 0.070 |
Why?
|
| Phenotype | 3 | 2017 | 947 | 0.070 |
Why?
|
| Risk Factors | 2 | 2014 | 5731 | 0.070 |
Why?
|
| Tumor Necrosis Factor Receptor-Associated Peptides and Proteins | 1 | 2006 | 4 | 0.070 |
Why?
|
| Heart | 1 | 2011 | 850 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2007 | 189 | 0.070 |
Why?
|
| Musculoskeletal Diseases | 1 | 2006 | 45 | 0.070 |
Why?
|
| Caspase 1 | 1 | 2006 | 22 | 0.070 |
Why?
|
| Taxoids | 1 | 2006 | 41 | 0.070 |
Why?
|
| Glucocorticoids | 1 | 2008 | 222 | 0.070 |
Why?
|
| Founder Effect | 1 | 2005 | 5 | 0.070 |
Why?
|
| Drug Stability | 2 | 2016 | 71 | 0.060 |
Why?
|
| Immunologic Factors | 1 | 2006 | 87 | 0.060 |
Why?
|
| Interleukin-1beta | 3 | 2013 | 88 | 0.060 |
Why?
|
| Protease Nexins | 2 | 1996 | 8 | 0.060 |
Why?
|
| RNA Interference | 2 | 2016 | 266 | 0.060 |
Why?
|
| Serpin E2 | 2 | 1996 | 8 | 0.060 |
Why?
|
| Atherosclerosis | 1 | 2007 | 204 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2005 | 282 | 0.060 |
Why?
|
| Caspase 3 | 4 | 2010 | 233 | 0.060 |
Why?
|
| Melanoma | 1 | 2008 | 335 | 0.060 |
Why?
|
| Ubiquitins | 1 | 2004 | 22 | 0.060 |
Why?
|
| Amyloid beta-Protein Precursor | 2 | 1996 | 115 | 0.060 |
Why?
|
| Somatomedins | 1 | 2004 | 16 | 0.060 |
Why?
|
| Multienzyme Complexes | 1 | 2004 | 50 | 0.060 |
Why?
|
| Cysteine Endopeptidases | 1 | 2004 | 39 | 0.060 |
Why?
|
| Gene Targeting | 1 | 2004 | 58 | 0.060 |
Why?
|
| Cricetulus | 1 | 2004 | 98 | 0.060 |
Why?
|
| Adolescent | 2 | 2014 | 8912 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2018 | 867 | 0.060 |
Why?
|
| Drug Synergism | 1 | 2004 | 260 | 0.060 |
Why?
|
| Mitochondrial Proteins | 2 | 2015 | 113 | 0.060 |
Why?
|
| Protein Kinases | 1 | 2004 | 122 | 0.060 |
Why?
|
| Islets of Langerhans | 1 | 2004 | 87 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 5 | 2007 | 852 | 0.060 |
Why?
|
| Depressive Disorder | 1 | 2007 | 621 | 0.060 |
Why?
|
| Muscle Strength | 2 | 2015 | 62 | 0.050 |
Why?
|
| Recombinant Proteins | 2 | 2018 | 742 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2002 | 189 | 0.050 |
Why?
|
| Peptide Hydrolases | 1 | 2002 | 82 | 0.050 |
Why?
|
| Coculture Techniques | 2 | 2014 | 147 | 0.050 |
Why?
|
| Administration, Oral | 2 | 2015 | 411 | 0.050 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 209 | 0.050 |
Why?
|
| Deoxycytidine | 2 | 2013 | 83 | 0.050 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2016 | 2083 | 0.050 |
Why?
|
| Base Sequence | 3 | 2001 | 1015 | 0.050 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 261 | 0.050 |
Why?
|
| Mitochondria, Liver | 1 | 2002 | 148 | 0.050 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 434 | 0.050 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2001 | 43 | 0.050 |
Why?
|
| Thalidomide | 1 | 2001 | 24 | 0.050 |
Why?
|
| Enzyme Activation | 4 | 2007 | 791 | 0.050 |
Why?
|
| Necrosis | 2 | 2011 | 239 | 0.050 |
Why?
|
| Body Weight | 2 | 2016 | 554 | 0.050 |
Why?
|
| Cell Communication | 2 | 2014 | 116 | 0.050 |
Why?
|
| Caspases | 4 | 2002 | 194 | 0.050 |
Why?
|
| Survival Rate | 2 | 2017 | 1056 | 0.050 |
Why?
|
| Carbidopa | 1 | 1980 | 3 | 0.050 |
Why?
|
| Levodopa | 1 | 1980 | 12 | 0.050 |
Why?
|
| Etanercept | 2 | 2013 | 12 | 0.050 |
Why?
|
| Interleukins | 1 | 2000 | 79 | 0.040 |
Why?
|
| Retroviridae Proteins, Oncogenic | 1 | 2000 | 9 | 0.040 |
Why?
|
| Fibrosis | 2 | 2012 | 371 | 0.040 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2022 | 266 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 1753 | 0.040 |
Why?
|
| Retrospective Studies | 3 | 2018 | 7277 | 0.040 |
Why?
|
| Consensus Sequence | 1 | 1999 | 20 | 0.040 |
Why?
|
| G1 Phase | 1 | 1999 | 42 | 0.040 |
Why?
|
| Age Factors | 2 | 2014 | 1864 | 0.040 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2019 | 42 | 0.040 |
Why?
|
| Dietary Fats | 1 | 2019 | 103 | 0.040 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 1999 | 88 | 0.040 |
Why?
|
| Fatigue | 2 | 2013 | 132 | 0.040 |
Why?
|
| ARNTL Transcription Factors | 1 | 2018 | 6 | 0.040 |
Why?
|
| Body Composition | 2 | 2011 | 119 | 0.040 |
Why?
|
| Bortezomib | 2 | 2009 | 45 | 0.040 |
Why?
|
| CLOCK Proteins | 1 | 2018 | 7 | 0.040 |
Why?
|
| Ultraviolet Rays | 1 | 2019 | 130 | 0.040 |
Why?
|
| Sendai virus | 1 | 2018 | 2 | 0.040 |
Why?
|
| THP-1 Cells | 1 | 2018 | 7 | 0.040 |
Why?
|
| Interferon Regulatory Factor-7 | 1 | 2018 | 4 | 0.040 |
Why?
|
| Chromatin | 1 | 2018 | 76 | 0.040 |
Why?
|
| Biomarkers | 2 | 2016 | 1593 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 1 | 1999 | 376 | 0.040 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 659 | 0.040 |
Why?
|
| HIV | 1 | 2018 | 56 | 0.040 |
Why?
|
| Mice, Inbred C3H | 2 | 2008 | 134 | 0.040 |
Why?
|
| Receptor, ErbB-3 | 1 | 2017 | 17 | 0.040 |
Why?
|
| Receptors, Thrombin | 1 | 1997 | 18 | 0.040 |
Why?
|
| Genetic Complementation Test | 1 | 2017 | 36 | 0.040 |
Why?
|
| Nutrition Therapy | 1 | 2017 | 21 | 0.040 |
Why?
|
| Allografts | 1 | 2017 | 63 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 1997 | 97 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2009 | 492 | 0.040 |
Why?
|
| Solid-Phase Synthesis Techniques | 1 | 2016 | 1 | 0.040 |
Why?
|
| Cytochrome c Group | 3 | 2002 | 22 | 0.040 |
Why?
|
| Pharmacokinetics | 1 | 2016 | 14 | 0.040 |
Why?
|
| Parkinson Disease | 1 | 1980 | 272 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2018 | 326 | 0.040 |
Why?
|
| Perioperative Care | 1 | 2017 | 100 | 0.040 |
Why?
|
| Treatment Outcome | 3 | 2017 | 7029 | 0.040 |
Why?
|
| Cell Membrane Permeability | 1 | 2016 | 59 | 0.040 |
Why?
|
| Tumor Protein p73 | 1 | 2016 | 4 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2017 | 151 | 0.030 |
Why?
|
| GATA1 Transcription Factor | 1 | 2016 | 19 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1996 | 95 | 0.030 |
Why?
|
| Morpholines | 1 | 2016 | 79 | 0.030 |
Why?
|
| Response Elements | 1 | 2016 | 29 | 0.030 |
Why?
|
| CCAAT-Enhancer-Binding Proteins | 1 | 2016 | 18 | 0.030 |
Why?
|
| Colony-Forming Units Assay | 1 | 2016 | 78 | 0.030 |
Why?
|
| Proteolysis | 1 | 2016 | 97 | 0.030 |
Why?
|
| History, 21st Century | 1 | 2016 | 127 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2016 | 47 | 0.030 |
Why?
|
| Sarcoma, Synovial | 1 | 2016 | 11 | 0.030 |
Why?
|
| Pulmonary Ventilation | 1 | 2016 | 28 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 1996 | 165 | 0.030 |
Why?
|
| Genetic Association Studies | 1 | 2016 | 103 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2017 | 536 | 0.030 |
Why?
|
| DNA Primers | 1 | 1996 | 302 | 0.030 |
Why?
|
| Transcription Factor AP-1 | 1 | 2016 | 61 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2016 | 45 | 0.030 |
Why?
|
| Leukemia Inhibitory Factor | 1 | 2015 | 3 | 0.030 |
Why?
|
| History, 20th Century | 1 | 2016 | 248 | 0.030 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2015 | 4 | 0.030 |
Why?
|
| Uncoupling Protein 3 | 1 | 2015 | 13 | 0.030 |
Why?
|
| SKP Cullin F-Box Protein Ligases | 1 | 2015 | 8 | 0.030 |
Why?
|
| Prospective Studies | 2 | 2017 | 3705 | 0.030 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2015 | 20 | 0.030 |
Why?
|
| Lipase | 1 | 2015 | 16 | 0.030 |
Why?
|
| Drug Discovery | 1 | 2016 | 94 | 0.030 |
Why?
|
| Behavior, Animal | 1 | 2018 | 470 | 0.030 |
Why?
|
| MEF2 Transcription Factors | 1 | 2015 | 36 | 0.030 |
Why?
|
| Proteins | 1 | 1999 | 474 | 0.030 |
Why?
|
| NF-kappa B p50 Subunit | 2 | 2009 | 12 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 196 | 0.030 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2015 | 20 | 0.030 |
Why?
|
| Caspase 8 | 2 | 2008 | 40 | 0.030 |
Why?
|
| Benzimidazoles | 1 | 2016 | 128 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2016 | 167 | 0.030 |
Why?
|
| Ion Channels | 1 | 2015 | 72 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2016 | 219 | 0.030 |
Why?
|
| Alleles | 1 | 2016 | 386 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2016 | 219 | 0.030 |
Why?
|
| Genetic Vectors | 2 | 2010 | 312 | 0.030 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 240 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2016 | 369 | 0.030 |
Why?
|
| Amino Acid Sequence | 1 | 2016 | 1083 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2009 | 507 | 0.030 |
Why?
|
| Interinstitutional Relations | 1 | 2014 | 49 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 1046 | 0.030 |
Why?
|
| Gene Expression | 2 | 2012 | 770 | 0.030 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2016 | 268 | 0.030 |
Why?
|
| Time Factors | 1 | 2002 | 4655 | 0.030 |
Why?
|
| Citric Acid Cycle | 1 | 2014 | 15 | 0.030 |
Why?
|
| Melanoma-Specific Antigens | 1 | 2014 | 3 | 0.030 |
Why?
|
| Child | 2 | 2016 | 6405 | 0.030 |
Why?
|
| Rats, Inbred BN | 1 | 2014 | 51 | 0.030 |
Why?
|
| Rats, Inbred F344 | 1 | 2014 | 104 | 0.030 |
Why?
|
| Primary Cell Culture | 1 | 2014 | 56 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 2014 | 71 | 0.030 |
Why?
|
| Superoxide Dismutase-1 | 1 | 2014 | 41 | 0.030 |
Why?
|
| Molecular Sequence Data | 1 | 1996 | 1447 | 0.030 |
Why?
|
| Intensive Care Units | 1 | 2016 | 344 | 0.030 |
Why?
|
| Dactinomycin | 1 | 1993 | 31 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1993 | 50 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2015 | 714 | 0.030 |
Why?
|
| Logistic Models | 1 | 2017 | 1420 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 332 | 0.030 |
Why?
|
| Amino Acids | 1 | 2014 | 131 | 0.030 |
Why?
|
| Superoxide Dismutase | 1 | 2014 | 149 | 0.030 |
Why?
|
| Nausea | 1 | 2013 | 47 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2016 | 627 | 0.030 |
Why?
|
| Dietary Supplements | 1 | 2016 | 332 | 0.030 |
Why?
|
| Fatty Acids | 1 | 2014 | 222 | 0.030 |
Why?
|
| eIF-2 Kinase | 1 | 2013 | 49 | 0.030 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 786 | 0.030 |
Why?
|
| Sarcolemma | 1 | 2012 | 16 | 0.030 |
Why?
|
| Interleukin-10 | 1 | 2013 | 144 | 0.030 |
Why?
|
| Endonucleases | 1 | 2012 | 10 | 0.030 |
Why?
|
| Progeria | 1 | 2012 | 6 | 0.030 |
Why?
|
| Combined Modality Therapy | 1 | 2015 | 951 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2016 | 1140 | 0.030 |
Why?
|
| Disease-Free Survival | 1 | 2013 | 349 | 0.030 |
Why?
|
| Erythroid Cells | 1 | 2012 | 5 | 0.030 |
Why?
|
| PAX5 Transcription Factor | 1 | 2012 | 9 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2012 | 51 | 0.030 |
Why?
|
| Anemia | 1 | 2013 | 104 | 0.030 |
Why?
|
| Interferon Regulatory Factors | 1 | 2012 | 24 | 0.030 |
Why?
|
| Cell Transdifferentiation | 1 | 2012 | 12 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 567 | 0.030 |
Why?
|
| Myositis | 1 | 2011 | 24 | 0.030 |
Why?
|
| Wnt1 Protein | 2 | 2002 | 9 | 0.020 |
Why?
|
| Mass Screening | 1 | 2018 | 843 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2013 | 314 | 0.020 |
Why?
|
| Receptors, Interferon | 1 | 2011 | 8 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2014 | 800 | 0.020 |
Why?
|
| Astrocytes | 1 | 2014 | 270 | 0.020 |
Why?
|
| Paired Box Transcription Factors | 1 | 2011 | 8 | 0.020 |
Why?
|
| Myofibroblasts | 1 | 2012 | 60 | 0.020 |
Why?
|
| Wnt Proteins | 2 | 2002 | 57 | 0.020 |
Why?
|
| PAX3 Transcription Factor | 1 | 2011 | 5 | 0.020 |
Why?
|
| Heterozygote | 1 | 2011 | 174 | 0.020 |
Why?
|
| Caspase 9 | 2 | 2001 | 31 | 0.020 |
Why?
|
| CD11b Antigen | 1 | 2011 | 47 | 0.020 |
Why?
|
| Myogenic Regulatory Factors | 1 | 2011 | 15 | 0.020 |
Why?
|
| STAT1 Transcription Factor | 1 | 2011 | 35 | 0.020 |
Why?
|
| Mitogens | 1 | 2011 | 45 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2011 | 120 | 0.020 |
Why?
|
| Interferon Type I | 1 | 2011 | 32 | 0.020 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 217 | 0.020 |
Why?
|
| Genes, p53 | 1 | 2011 | 41 | 0.020 |
Why?
|
| Nitric Oxide Donors | 1 | 2011 | 54 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 3259 | 0.020 |
Why?
|
| Nerve Regeneration | 1 | 2011 | 42 | 0.020 |
Why?
|
| Indoles | 1 | 2011 | 146 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2011 | 153 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2014 | 631 | 0.020 |
Why?
|
| DNA Probes | 2 | 2001 | 57 | 0.020 |
Why?
|
| Hepatocytes | 1 | 2012 | 205 | 0.020 |
Why?
|
| Obesity | 1 | 2018 | 1076 | 0.020 |
Why?
|
| Hand Strength | 1 | 2010 | 47 | 0.020 |
Why?
|
| Breast Neoplasms | 1 | 2000 | 1536 | 0.020 |
Why?
|
| Cecum | 1 | 2010 | 39 | 0.020 |
Why?
|
| Punctures | 1 | 2010 | 35 | 0.020 |
Why?
|
| Serum Amyloid A Protein | 1 | 2010 | 33 | 0.020 |
Why?
|
| Ligation | 1 | 2010 | 83 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2011 | 306 | 0.020 |
Why?
|
| Random Allocation | 1 | 2011 | 442 | 0.020 |
Why?
|
| Postoperative Complications | 1 | 2017 | 1615 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2010 | 272 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2016 | 2358 | 0.020 |
Why?
|
| Chromatography, Liquid | 1 | 2010 | 120 | 0.020 |
Why?
|
| Patched Receptors | 1 | 2009 | 2 | 0.020 |
Why?
|
| Patched-1 Receptor | 1 | 2009 | 2 | 0.020 |
Why?
|
| Zebrafish | 1 | 2010 | 187 | 0.020 |
Why?
|
| Loss of Heterozygosity | 1 | 2009 | 25 | 0.020 |
Why?
|
| Prevalence | 1 | 2014 | 1619 | 0.020 |
Why?
|
| Hedgehog Proteins | 1 | 2009 | 38 | 0.020 |
Why?
|
| Pneumonia | 1 | 2010 | 110 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 254 | 0.020 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 2008 | 7 | 0.020 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2008 | 19 | 0.020 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2008 | 39 | 0.020 |
Why?
|
| Histone Deacetylases | 1 | 2009 | 99 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2009 | 489 | 0.020 |
Why?
|
| Leukotriene A4 | 1 | 2008 | 2 | 0.020 |
Why?
|
| Interleukin-1alpha | 1 | 2008 | 5 | 0.020 |
Why?
|
| Celecoxib | 1 | 2008 | 22 | 0.020 |
Why?
|
| Echocardiography | 1 | 2011 | 515 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 214 | 0.020 |
Why?
|
| Oxidative Stress | 1 | 2012 | 718 | 0.020 |
Why?
|
| Tongue Neoplasms | 1 | 2008 | 29 | 0.020 |
Why?
|
| Hindlimb | 1 | 2008 | 38 | 0.020 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2008 | 46 | 0.020 |
Why?
|
| Carcinogens | 1 | 2008 | 86 | 0.020 |
Why?
|
| Matrix Metalloproteinase 13 | 1 | 2007 | 24 | 0.020 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2007 | 55 | 0.020 |
Why?
|
| Umbilical Veins | 1 | 2007 | 54 | 0.020 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2008 | 110 | 0.020 |
Why?
|
| Transplantation, Heterologous | 1 | 2007 | 122 | 0.020 |
Why?
|
| HTLV-I Infections | 1 | 2007 | 3 | 0.020 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2007 | 45 | 0.020 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2007 | 52 | 0.020 |
Why?
|
| Chloramphenicol O-Acetyltransferase | 1 | 2007 | 26 | 0.020 |
Why?
|
| Kidney Neoplasms | 1 | 2008 | 206 | 0.020 |
Why?
|
| Nutritional Support | 1 | 2007 | 22 | 0.020 |
Why?
|
| Mice, Inbred NOD | 1 | 2007 | 138 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2007 | 204 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2008 | 190 | 0.020 |
Why?
|
| Antibodies, Viral | 1 | 2007 | 110 | 0.020 |
Why?
|
| Syndrome | 1 | 2007 | 255 | 0.020 |
Why?
|
| Asthenia | 1 | 2006 | 2 | 0.020 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinase 2 | 1 | 2006 | 1 | 0.020 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2006 | 3 | 0.020 |
Why?
|
| Biomechanical Phenomena | 1 | 2007 | 368 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2006 | 25 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 87 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2010 | 1465 | 0.020 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2006 | 30 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2006 | 100 | 0.020 |
Why?
|
| Liver | 1 | 2011 | 1118 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 2006 | 765 | 0.020 |
Why?
|
| Activating Transcription Factor 3 | 1 | 2004 | 4 | 0.020 |
Why?
|
| Glucagon | 1 | 2004 | 22 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2007 | 384 | 0.010 |
Why?
|
| Pancreas | 1 | 2004 | 225 | 0.010 |
Why?
|
| U937 Cells | 1 | 2002 | 61 | 0.010 |
Why?
|
| CCN Intercellular Signaling Proteins | 1 | 2002 | 3 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 2002 | 351 | 0.010 |
Why?
|
| Caspase Inhibitors | 1 | 2002 | 36 | 0.010 |
Why?
|
| Oncogene Proteins | 1 | 2002 | 35 | 0.010 |
Why?
|
| Growth Substances | 1 | 2002 | 77 | 0.010 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2002 | 73 | 0.010 |
Why?
|
| Smad5 Protein | 1 | 2001 | 3 | 0.010 |
Why?
|
| Trypan Blue | 1 | 2001 | 24 | 0.010 |
Why?
|
| Bone Morphogenetic Protein 4 | 1 | 2001 | 17 | 0.010 |
Why?
|
| Smad Proteins | 1 | 2001 | 25 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2001 | 51 | 0.010 |
Why?
|
| Bone Morphogenetic Protein 2 | 1 | 2001 | 57 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2001 | 59 | 0.010 |
Why?
|
| Transcription Factor 7-Like 2 Protein | 1 | 2001 | 6 | 0.010 |
Why?
|
| TCF Transcription Factors | 1 | 2001 | 5 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2007 | 824 | 0.010 |
Why?
|
| Insulin | 1 | 2004 | 619 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2002 | 308 | 0.010 |
Why?
|
| beta Catenin | 1 | 2001 | 73 | 0.010 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2001 | 140 | 0.010 |
Why?
|
| Mesoderm | 1 | 2001 | 231 | 0.010 |
Why?
|
| NF-kappa B p52 Subunit | 1 | 2000 | 1 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2000 | 3 | 0.010 |
Why?
|
| Oncogene Protein v-akt | 1 | 2000 | 25 | 0.010 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 1999 | 2 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2001 | 250 | 0.010 |
Why?
|
| Etoposide | 1 | 1999 | 64 | 0.010 |
Why?
|
| Transgenes | 1 | 1999 | 92 | 0.010 |
Why?
|
| Transduction, Genetic | 1 | 1999 | 81 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2000 | 195 | 0.010 |
Why?
|
| Adenoviridae | 1 | 1999 | 295 | 0.010 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 694 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2001 | 561 | 0.010 |
Why?
|
| Pregnancy | 1 | 1980 | 2334 | 0.010 |
Why?
|